nach oben

Erschienen in:

22.08.2018 | Original Article

Association of CD26/dipeptidyl peptidase IV mRNA level in peripheral blood mononuclear cells with disease activity and bone erosion in rheumatoid arthritis

verfasst von: Farshid Yeganeh, Seyed Mohammad Javad Mousavi, Saeed Hosseinzadeh-Sarband, Arman Ahmadzadeh, Hooman Bahrami-Motlagh, Mostafa Haji Molla Hoseini, Mandana Sattari, Mohammad Reza Sohrabi, Ramin Pouriran, Pooneh Dehghan

Erschienen in: Clinical Rheumatology | Ausgabe 12/2018

Einloggen, um Zugang zu erhalten

Abstract

Dipeptidyl peptidase IV (DPP-IV, CD26) plays many roles in the pathogenesis of several autoimmune and inflammatory diseases. The current study evaluated the association of DPP-IV enzymatic activity and its gene expression with disease activity and bone erosion in rheumatoid arthritis. Blood samples were collected from 20 rheumatoid arthritis patients and 40 healthy volunteers. Patients were divided into four subgroups using DAS28 index. CD26 gene expression levels were analyzed in peripheral blood mononuclear cells by quantitative reverse transcription-polymerase chain reaction. Additionally, the enzymatic activity of this molecule in serum was determined using Gly-Pro-p-nitroanilide as substrate. Digital radiography was applied to obtain images for bone erosion assessment. No significant difference in serum DPP-IV activity level was seen between patients and controls (p = 0.140). However, patients exhibited an increase in CD26 mRNA expression (1.68 times) when compared to controls (p = 0.001). Moreover, a strong positive correlation between CD26 gene expression and DAS28 index as well as bone erosion in the hands was observed (r = 0.71, p = 0.002 and r = 0.61, p = 0.049, respectively). This study demonstrated that CD26 mRNA expression in rheumatoid arthritis patients is associated with disease activity and bone erosion, suggesting a potential role for this molecule in the immunopathology of rheumatoid arthritis and bone erosion.

Cross M, Smith E, Hoy D, Carmona L, Wolfe F, Vos T, Williams B, Gabriel S, Lassere M, Johns N, Buchbinder R, Woolf A, March L (2014) The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis 73:1316–1322. https://doi.org/10.1136/annrheumdis-2013-204627 CrossRefPubMed

Lubberts E (2015) The IL-23–IL-17 axis in inflammatory arthritis. Nat Rev Rheumatol 11:415–429. https://doi.org/10.1038/nrrheum.2015.53 CrossRefPubMed

Murphy G, Knäuper V, Atkinson S, Butler G, English W, Hutton M, Stracke J, Clark I (2002) Matrix metalloproteinases in arthritic disease. Arthritis Res 4(Suppl 3):S39–S49. https://doi.org/10.1186/ar572. CrossRefPubMedPubMedCentral

Proost P, De Meester I, Schols D, Struyf S, Lambeir AM, Wuyts A, Opdenakker G, De Clercq E, Scharpé S, Van Damme J (1998) Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection. J Biol Chem 273:7222–7227CrossRefPubMed

Shioda T, Kato H, Ohnishi Y, Tashiro K, Ikegawa M, Nakayama EE, Hu H, Kato A, Sakai Y, Liu H, Honjo T, Nomoto A, Iwamoto A, Morimoto C, Nagai Y (1998) Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1alpha (SDF-1alpha) and SDF-1beta are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage. Proc Natl Acad Sci U S A 95:6331–6336CrossRefPubMedPubMedCentral

Sedo A, Duke-Cohan JS, Balaziova E, Sedova LR (2005) Dipeptidyl peptidase IV activity and/or structure homologs: contributing factors in the pathogenesis of rheumatoid arthritis? Arthritis Res Ther 7:253–269. https://doi.org/10.1186/ar1852. CrossRefPubMedPubMedCentral

Richard E, Arredondo-Vega FX, Santisteban I, Kelly SJ, Patel DD, Hershfield MS (2000) The binding site of human adenosine deaminase for CD26/dipeptidyl peptidase IV: the Arg142Gln mutation impairs binding to cd26 but does not cause immune deficiency. J Exp Med 192:1223–1236CrossRefPubMedPubMedCentral

Ohnuma K, Uchiyama M, Yamochi T, Nishibashi K, Hosono O, Takahashi N, Kina S, Tanaka H, Lin X, Dang NH, Morimoto C (2007) Caveolin-1 triggers T-cell activation via CD26 in association with CARMA1. J Biol Chem 282:10117–10131. https://doi.org/10.1074/jbc.M609157200 CrossRefPubMed

Ishii T, Ohnuma K, Murakami A, Takasawa N, Kobayashi S, Dang NH, Schlossman SF, Morimoto C (2001) CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO. Proc Natl Acad Sci 98:12138–12143. https://doi.org/10.1073/pnas.211439098 CrossRefPubMedPubMedCentral

10.

Cordero OJ, Varela-Calviño R, López-González T, Calviño-Sampedro C, Viñuela JE, Mouriño C, Hernández-Rodríguez Í, Rodríguez-López M, Aspe de la Iglesia B, Pego-Reigosa JM, Pego JM (2015) CD26 expression on T helper populations and sCD26 serum levels in patients with rheumatoid arthritis. PLoS One 10:e0131992. https://doi.org/10.1371/journal.pone.0131992 CrossRefPubMedPubMedCentral

11.

Wesley UV, Tiwari S, Houghton AN (2004) Role for dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells. Int J Cancer 109(6):855–866. https://doi.org/10.1002/ijc.20091 CrossRefPubMed

12.

Matic IZ, Djordjic M, Grozdanic N, Damjanovic A, Kolundzija B, Eric-Nikolic A, Dzodic R, Sasic M, Dobrosavljevic D, Raskovic S, Andrejevic S, Gavrilovic D, Cordero OJ, Juranic ZD, Juranić ZD (2012) Serum activity of DPPIV and its expression on lymphocytes in patients with melanoma and in people with vitiligo. BMC Immunol 13(48):48. https://doi.org/10.1186/1471-2172-13-48. CrossRefPubMedPubMedCentral

13.

Hosono O, Homma T, Kobayashi H, Munakata Y, Nojima Y, Iwamoto A, Morimoto C (1999) Decreased dipeptidyl peptidase IV enzyme activity of plasma soluble CD26 and its inverse correlation with HIV-1 RNA in HIV-1 infected individuals. Clin Immunol 91:283–295. https://doi.org/10.1006/clim.1999.4711 CrossRefPubMed

14.

Sedo A, Malik R, Votruba M, Hanic T, Hanic O (1996) Serum dipeptidyl peptidase IV activities in Czernobyl zone inhabitants exposed to the power-station catastrophe. Eur J Clin Chem Clin Biochem 34:447–448PubMed

15.

Valizadeh M, Amadzadeh A, Behzadi M, Yeganeh F (2018) CD26 mRNA expression in systemic lupus erythematosus. Rheum Res 3:77–82. https://doi.org/10.22631/RR.2018.69997.1045 CrossRef

16.

Mostafa HM, Ali-Akbar P, Zahra S, Minoo M, Sedigheh A, Mahnaz A, Shahram S, Mahin N, Mina M (2007) Soluble CD26 and CD30 plasma levels in HIV infected patients with and without GB virus type C coinfection. Pakistan J Biol Sci 10:2014–2019. https://doi.org/10.3923/pjbs.2007.2014.2019 CrossRef

17.

Grujic M, Matic IZ, Crnogorac MD, Velickovic AD, Kolundzija B, Cordero OJ, Juranic Z, Prodanovic S, Zlatanovic M, Babic D, Damjanov N (2017) Activity and expression of dipeptidyl peptidase IV on peripheral blood mononuclear cells in patients with early steroid and disease modifying antirheumatic drugs naïve rheumatoid arthritis. Clin Chem Lab Med 55:73–81. https://doi.org/10.1515/cclm-2015-1279 CrossRefPubMed

18.

Sromova L, Busek P, Sedova L, Sedo A (2015) Intraindividual changes of dipeptidyl peptidase-IV in peripheral blood of patients with rheumatoid arthritis are associated with the disease activity. BMC Musculoskelet Disord 16:244. https://doi.org/10.1186/s12891-015-0707-y CrossRefPubMedPubMedCentral

19.

Cordero OJ, Salgado FJ, Mera-Varela A, Nogueira M (2001) Serum interleukin-12, interleukin-15, soluble CD26, and adenosine deaminase in patients with rheumatoid arthritis. Rheumatol Int 21:69–74CrossRefPubMed

20.

Tanaka S, Murakami T, Horikawa H, Sugiura M, Kawashima K, Sugita T (1997) Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV. Int J Immunopharmacol 19:15–24CrossRefPubMed

21.

Busso N, Wagtmann N, Herling C, Chobaz-Péclat V, Bischof-Delaloye A, So A, Grouzmann E (2005) Circulating CD26 is negatively associated with inflammation in human and experimental arthritis. Am J Pathol 166:433–442. https://doi.org/10.1016/S0002-9440(10)62266-3 CrossRefPubMedPubMedCentral

22.

Schett G, Gravallese E (2012) Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat Rev Rheumatol 8:656–664. https://doi.org/10.1038/nrrheum.2012.153 CrossRefPubMedPubMedCentral

23.

De Meester I, Lambeir A-M, Proost P, Scharpé S (2004) Dipeptidyl peptidase IV substrates. Adv Exp Med Biol:3–17. https://doi.org/10.1007/0-306-47920-6_1. CrossRef

24.

Glorie L, Behets GJ, Baerts L, De Meester I, D’Haese PC, Verhulst A (2014) DPP IV inhibitor treatment attenuates bone loss and improves mechanical bone strength in male diabetic rats. Am J Physiol Metab 307(5):E447–E455. https://doi.org/10.1152/ajpendo.00217.2014 CrossRef

25.

Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JMW, Hobbs K, Huizinga TWJ, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovský J, Wolfe F, Hawker G (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569–2581. https://doi.org/10.1002/art.27584 CrossRefPubMed

26.

Ellingsen T, Hansen I, Thorsen J, Kuno Møller B, Tarp U, Jacobsen S, Lund Hetland M, Vestergaard A, Hørslev-Petersen K, Stengaard-Pedersen K (2012) Up-regulated dipeptidyl-peptidase IV (CD26) on monocytes was unaffected by effective DMARD treatment in early steroid and DMARD-naive rheumatoid arthritis. Clin Exp Rheumatol 30:58–63PubMed

27.

Sell H, Blüher M, Klöting N, Schlich R, Willems M, Ruppe F, Knoefel WT, Dietrich A, Fielding BA, Arner P, Frayn KN, Eckel J (2013) Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro. Diabetes Care 36:4083–4090. https://doi.org/10.2337/dc13-0496 CrossRefPubMedPubMedCentral

28.

Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3(7):research0034.1. https://doi.org/10.1186/gb-2002-3-7-research0034 CrossRef

29.

Beckenkamp A, Willig JB, Santana DB, Nascimento J, Paccez JD, Zerbini LF, Bruno AN, Pilger DA, Wink MR, Buffon A (2015) Differential expression and enzymatic activity of DPPIV/CD26 affects migration ability of cervical carcinoma cells. PLoS One 10:e0134305. https://doi.org/10.1371/journal.pone.0134305 CrossRefPubMedPubMedCentral

30.

van der Heijde D (2000) How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 27:261–263. https://doi.org/10.1002/art.22835. CrossRefPubMed

31.

Durinx C, Neels H, Van der Auwera J-C, Naelaerts K, Scharpé S, De Meester I (2001) Reference values for plasma dipeptidyl peptidase IV activity and their association with other laboratory parameters. Clin Chem Lab Med 39:155–159. https://doi.org/10.1515/CCLM.2001.026 CrossRefPubMed

32.

Cuchacovich M, Gatica H, Pizzo SV, Gonzalez-Gronow M (2001) Characterization of human serum dipeptidyl peptidase IV (CD26) and analysis of its autoantibodies in patients with rheumatoid arthritis and other autoimmune diseases. Clin Exp Rheumatol 19(6):673–680PubMed

33.

Mantle D, Falkous G, Walker D (1999) Quantification of protease activities in synovial fluid from rheumatoid and osteoarthritis cases: comparison with antioxidant and free radical damage markers. Clin Chim Acta 284:45–58CrossRefPubMed

34.

Yamasaki SC, Murari-do-Nascimento S, Silveira PF (2012) Neutral aminopeptidase and dipeptidyl peptidase IV in the development of collagen II-induced arthritis. Regul Pept 173:47–54. https://doi.org/10.1016/J.REGPEP.2011.09.004 CrossRefPubMed

35.

Buljevic S, Detel D, Pucar LB, Mihelic R, Madarevic T, Sestan B, Varljen J (2013) Levels of dipeptidyl peptidase IV/CD26 substrates neuropeptide Y and vasoactive intestinal peptide in rheumatoid arthritis patients. Rheumatol Int 33:2867–2874. https://doi.org/10.1007/s00296-013-2823-z CrossRefPubMed

36.

Mavropoulos JC, Cuchacovich M, Llanos C, Aguillón JC, Gatica H, Pizzo SV, Gonzalez-Gronow M (2005) Anti-tumor necrosis factor-alpha therapy augments dipeptidyl peptidase IV activity and decreases autoantibodies to GRP78/BIP and phosphoglucose isomerase in patients with rheumatoid arthritis. J Rheumatol 32:2116–2124PubMed

37.

Dang NH, Torimoto Y, Sugita K, Daley JF, Schow P, Prado C, Schlossman SF, Morimoto C (1990) Cell surface modulation of CD26 by anti-1F7 monoclonal antibody. Analysis of surface expression and human T cell activation. J Immunol 145:3963–3971PubMed

38.

Hanski C, Huhle T, Reutter W (1985) Involvement of plasma membrane dipeptidyl peptidase IV in fibronectin-mediated adhesion of cells on collagen. Biol Chem Hoppe Seyler 366:1169–1176CrossRefPubMed

39.

Klemann C, Wagner L, Stephan M, von Hörsten S (2016) Cut to the chase: a review of CD26/dipeptidyl peptidase-4’s (DPP4) entanglement in the immune system. Clin Exp Immunol 185:1–21. https://doi.org/10.1111/cei.12781. CrossRefPubMedPubMedCentral

40.

Cordero OJ, Salgado FJ, Viñuela JE, Nogueira M (1997) Interleukin-12 enhances CD26 expression and dipeptidyl peptidase IV function on human activated lymphocytes. Immunobiology 197:522–533. https://doi.org/10.1016/S0171-2985(97)80084-8 CrossRefPubMed

41.

Wolczyk D, Zaremba-Czogalla M, Hryniewicz-Jankowska A, Tabola R, Grabowski K, Sikorski AF, Augoff K (2016) TNF-α promotes breast cancer cell migration and enhances the concentration of membrane-associated proteases in lipid rafts. Cell Oncol (Dordr) 39:353–363. https://doi.org/10.1007/s13402-016-0280-x CrossRef

42.

Bengsch B, Seigel B, Flecken T, Wolanski J, Blum HE, Thimme R (2012) Human Th17 cells express high levels of enzymatically active dipeptidylpeptidase IV (CD26). J Immunol 188:5438–5447. https://doi.org/10.4049/jimmunol.1103801 CrossRefPubMed

43.

Nishida H, Suzuki H, Madokoro H, Hayashi M, Morimoto C, Sakamoto M, Yamada T (2014) Blockade of CD26 signaling inhibits human osteoclast development. J Bone Miner Res 29:2439–2455. https://doi.org/10.1002/jbmr.2277 CrossRefPubMed

44.

Monami M, Dicembrini I, Antenore A, Mannucci E (2011) Dipeptidyl Peptidase-4 inhibitors and bone fractures. Diabetes Care 34:2474–2476. https://doi.org/10.2337/DC11-1099. CrossRefPubMedPubMedCentral

45.

Driessen JH, van den Bergh JP, van Onzenoort HA, Henry RM, Leufkens HG, de Vries F (2017) Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: a retrospective population-based cohort study. Diabetes Obes Metab 19(3):421–428. https://doi.org/10.1111/dom.12843. CrossRefPubMed

46.

Kumagai Y, Konishi K, Gomi T, Yagishita H, Yajima A, Yoshikawa M (2000) Enzymatic properties of dipeptidyl aminopeptidase IV produced by the periodontal pathogen Porphyromonas gingivalis and its participation in virulence. Infect Immun 68:716–724. https://doi.org/10.1128/IAI.68.2.716-724.2000 CrossRefPubMedPubMedCentral

47.

Koziel J, Mydel P, Potempa J (2014) The link between periodontal disease and rheumatoid arthritis: an updated review. Curr Rheumatol Rep 16:408. https://doi.org/10.1007/s11926-014-0408-9 CrossRefPubMedPubMedCentral

Titel: Association of CD26/dipeptidyl peptidase IV mRNA level in peripheral blood mononuclear cells with disease activity and bone erosion in rheumatoid arthritis
verfasst von: Farshid Yeganeh
Seyed Mohammad Javad Mousavi
Saeed Hosseinzadeh-Sarband
Arman Ahmadzadeh
Hooman Bahrami-Motlagh
Mostafa Haji Molla Hoseini
Mandana Sattari
Mohammad Reza Sohrabi
Ramin Pouriran
Pooneh Dehghan
Publikationsdatum: 22.08.2018
Verlag: Springer London
Erschienen in: Clinical Rheumatology / Ausgabe 12/2018
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-018-4268-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2018

A note from the Editor

Telomere dysfunction-related serological markers and oxidative stress markers in rheumatoid arthritis patients: correlation with diseases activity

Socio-economic gradients in the presence of musculoskeletal and other chronic diseases: results from a cross-sectional study in the Netherlands

Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature

Do SNPs in folate pharmacokinetic pathway alter levels of intracellular methotrexate polyglutamates and affect response? A prospective study in Indian patients